Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Cripe

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|May 20, 2017
Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule DrugsMark A Currier, Justine R Stehn, Ashleigh Swain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2017
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer PatientsKeri A Streby, James I Geller, Mark A Currier, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Molecular Therapy. Oncology|November 4, 2024
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2024
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneouslyWen Luo, Hai Hoang, Katherine E Miller, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone SarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
Molecular Therapy Oncolytics|April 28, 2016
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L Leddon, Chun-Yu Chen, Mark A Currier, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|May 20, 2017
Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule DrugsMark A Currier, Justine R Stehn, Ashleigh Swain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2017
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer PatientsKeri A Streby, James I Geller, Mark A Currier, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
Molecular Therapy. Oncology|November 4, 2024
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2024
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneouslyWen Luo, Hai Hoang, Katherine E Miller, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone SarcomaEmily M Ringwalt, Mark A Currier, Andrea M Glaspell, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
Molecular Therapy Oncolytics|April 28, 2016
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L Leddon, Chun-Yu Chen, Mark A Currier, et al.
Pageof 13